Site Overlay

International Guest Speakers – Annual Conference 2023

Prof. Kevin J. Harrington FRCP FRCR FRSB PhD

Professor in Biological Cancer Therapies

kevin-j-harringtonKevin Harrington is an NIHR Senior Investigator and Head of the Division of Radiotherapy and Imaging at The Institute of Cancer Research (ICR)/Royal Marsden Hospital (RMH). He is the RMH/ICR NIHR Biomedical Research Centre lead for the Targeted Physical Therapies theme, Director for the ICR/RM CRUK RadNet Centre of Excellence, Chair of the CRUK Advanced Radiotherapy Network (ART-NET) Network Accelerator, Chair of the ICR Wellcome Trust Clinical Training Programme and an Executive Board member for the CRUK ICR/Imperial Major Centre for Convergence Science. He is also an Honorary Consultant Clinical Oncologist at The Royal Marsden NHS Foundation Trust and at St George’s Hospital, specialising in developing new treatments with a specific focus on head and neck cancer (HNC).

His research interests include immunotherapy, targeted radiation sensitisers and oncolytic virotherapy. In the field of immunotherapy for cancer, he has been involved in the development of immune checkpoint inhibitors (PD-1, PD-L1, CTLA-4, TIGIT, CD47 inhibitors) and innate immune activators (eg cyclic dinucleotide (CDN) and non-CDN STING agonists). He serves on Steering Committees and Scientific Advisory Boards that have guided the development of trials of immune checkpoint inhibitors in head and neck cancer (including Keynote-040, -048, -412, -689, CheckMate-141, -651, 714, Kestrel, Javelin-100). He has been Principal Investigator of multiple phase I, II and III studies of novel agents in HNC. He leads a programme of pre-clinical and clinical research in targeted radiosensitisers (Chk1i, HSP90i, ATRi), including the first-in-man phase I PATRIOT study of the ATR inhibitor, AZD6738. This work focuses largely on the potential immunological effects of combinations of DNA damage response inhibition and radiation. In oncolytic virotherapy, he has led in developing DNA (HSV [talimogene laherparepvec, RP1, RP2 and RP3 viruses] and vaccinia virus) and RNA viruses (Reovirus type 3 Dearing, coxsackievirus A21, Maraba and Newcastle Disease virus).

His expertise has been recognized in membership of multiple national and international practice-defining guideline committees: British Association of Head and Neck Oncology (BAHNO), UK National Multidisciplinary guidelines (2011, 2015); Chair, UK Head and Neck Mucosal Melanoma Group (2018-2020); International Nasopharynx Cancer guidelines (2018, 2019, 2020); Human Intratumoural Immunotherapy (HIT-IT) (2018); Society for Immunotherapy of Cancer (SITC) HNC guidelines (2019); Intratumoural RECIST Guideline Group (2019-2020); ASTRO/ESTRO guideline group to define risk-adapted radiotherapy in COVID patients with HNC (2020); founding Steering Committee member of the ESMO Co-CARE Registry (2020); SITC Intratumoural Therapy Expert Panel (2022).

He received the 2019 BAHNO President’s Achievement Award and was the 2021 Semon Lecturer (Royal Society of Medicine).

Prof. Harrington has published >570 peer-reviewed publications and >50 book chapters. He was listed as a Clarivate Highly Cited Researcher in 2021 and 2022.


Dr Justin Roe

DR Justin Roe

Dr Justin Roe is a Consultant and Professional Lead for Speech and Language Therapy at the Royal Marsden NHS Foundation Trust in London. He is also the Clinical Service Lead for the Complex Laryngology Service/ National Centre for Airway Reconstruction at Imperial College Healthcare NHS Trust. He is an Honorary Clinical Senior Lecturer in the Department of Surgery and Cancer at Imperial College London.

Justin was awarded a PhD in 2013 from the Institute of Cancer Research in London He is now actively involved in a number of Cancer Research UK and National Institute for Health Research (NIHR) portfolio studies. He is the survivorship theme lead for the International Centre for Recurrent Head and Neck Cancer (IReC) delivered by the Royal Marsden.

Justin has contributed to key policy and position papers and is an expert adviser to several national organisations. He is a Council Member for the British Association of Head and Neck Oncologists and the British Laryngological Association. He was awarded the Fellowship of the Royal College of Speech and Language Therapists in 2018 and an MBE in the 2022 Queen’s New Year Honours in recognition of his contribution to the profession.


Ralph Gilbert

Ralph Gilbert


Dr Patrick Gullane

Dr Patrick GullaneDr Patrick Gullane was born in Ireland and received his medical degree from NUI-Galway, Ireland.  He is a Fellow of the Royal College of Surgeons of Canada and certified by the American Board of Otolaryngology-Head and Neck Surgery.  In 1975 he was selected as the McLaughlin Fellow and then pursued advanced Fellowship training in Head and Neck Oncology in Pittsburgh, and New York.

In 1978, Dr Gullane was appointed to the Department of Otolaryngology-Head and Neck Surgery at the University of Western Ontario, Canada.  He was subsequently recruited in 1983 to the Department of Otolaryngology-Head and Neck Surgery at the University of Toronto. He currently holds the Wharton Chair in Head and Neck Surgery at the University Health Network and University of Toronto.   In 1989 he was appointed as Otolaryngologist-in-Chief within the University Health Network and in 2002 appointed as Professor and Chair of the Department of Otolaryngology-Head and Neck Surgery, University of Toronto.

Dr Gullane is a member of numerous Surgical Societies, nationally/internationally and has been invited as a Visiting Professor to over 65 countries lecturing on all aspects of Head and Neck Oncology.  He has delivered over 635 invited and Keynote presentations nationally/internationally including the Eugene Myers International lecture in September 2006, received the 2007 Medtronic Alumni Award from the National University of Ireland (Galway) for contributions to Health Care and Medical Science, delivered the Sir Peter Freyer Memorial lecture to the Irish Surgical Forum NUI-Galway in 2009, the John J.  Conley lecture to the American Head and Neck Society in 2012, the 87th Abraham Colles lecture at the Royal College of Surgeons in Ireland in February 2012, the Hayes Martin lecture at the 5th World Congress of IFHNOS and annual meeting of the Head and Neck Society in New York in July 2014 and the Gunnar Holmgren Lecture to the Swedish Society of Otolaryngology-Head and Neck Surgery April 2018.   He was one of the six International Faculty leaders who conducted the IFHNOS Head and Neck World Tour Program in 2008. Dr Gullane has published 368 papers in peer-reviewed journals and 98 chapters in textbooks.  In addition he has published 10 books on various aspects of Head and Neck Surgery. He has served as President of the American Head & Neck Society, The North American Skull Base Society, President of the Canadian Society of Otolaryngology-Head and Neck Surgery and Vice President of the Triological Society. In recognition of his distinguished achievements, Professor Gullane was awarded an Honorary Fellowship of the Royal Australasian College of Surgeons in 2006, Honorary Fellowship of the Royal College of Surgeons of England in 2010 and an Honorary Fellowship in the Royal College of Surgeons of Ireland in 2012. He was elected to Fellowship in the Canadian Academy of Health Sciences in 2011 and in 2010 was appointed as a Member to the Order of Canada by the Governor General of Canada, Cited for his inspiration of young surgeons and his contributions to the field of Head and Neck Surgery. In 2014, in recognition of his outstanding contributions an endowed Chair was named in his honour at the University Health Network/University of Toronto.  In February 2015, Dr Gullane was appointed as a Member to the Order of Ontario by the Lieutenant Governor of Ontario for his achievements in the field of Head and Neck Surgery. In June 2022 he was awarded an Hon. Doctorate from Western University, London, Ontario. Finally, he has facilitated the establishment of Six University-Hospital Chairs: Head & Neck Surgery, Reconstruction, Radiation Oncology, and Basic Science, from private funding donations in excess of $19.5 M., with continual funding up to the present time.